Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares

HighVista Strategies sold 70,503 shares of Maze Therapeutics in Q1 2026 for an estimated $3.11 million, reducing its stake to 99,850 shares valued at $2.98 million and trimming the position to 0.82% of reported AUM. The sale came after Maze shares had risen about 180% over the past year, suggesting profit-taking rather than a fundamental negative signal. The company remains a clinical-stage biotech with ongoing interest in MZE829, but the filing itself is a moderate positioning update rather than a major catalyst.

Analysis

HighVista’s trim looks more like de-risking into volatility than a true thesis break. When a small-cap biotech has already re-rated sharply, the marginal buyer gets less forgiving, so even good clinical updates can stop helping if the next leg of value creation is pushed out to a 2027 pivotal. That creates a classic “data-good, stock-bad” setup where the market discounts execution risk more aggressively than pipeline quality.

The second-order issue is timing: the stock is now living off a proof-of-concept narrative while the real catalyst is a much longer-duration regulatory and financing path. That usually favors investors who can tolerate a dead-money period, but it also increases the odds of multiple compression if broader biotech risk appetite softens. In that regime, competitors with more advanced kidney assets can absorb incremental attention and capital even if Maze’s biology remains credible.

The sell-down is also a useful signal on crowding. When a hedge fund keeps a residual position after monetizing a chunk of gains, it often means the name is still interesting but no longer cheap enough to justify full sizing. The market may be underpricing how much of Maze’s valuation is now contingent on a clean sequence of follow-up data rather than the first encouraging readout.

Contrarian view: the post-data drawdown may have already done part of the work for bears, so chasing a short here is less attractive than fading strength into any enthusiasm spike. The better edge is likely in relative value: if Maze remains range-bound while the sector re-rates, it can underperform higher-quality or later-stage kidney exposure without needing any fundamental deterioration.

Key Decisions for Investors

• Avoid initiating fresh long MAZE here; wait for either a retracement or confirmation of the next clinical milestone, because the setup is now more execution-dependent than science-dependent over the next 6-12 months.
• If already long MAZE, trim 25-50% on strength and keep a core position for the 2027 pivotal-trial catalyst; the upside is still meaningful, but the path is now too long to justify full beta exposure.
• Relative-value trade: long a more de-risked kidney/biotech developer with nearer-term clinical visibility versus short MAZE, targeting 3-6 months of multiple divergence if biotech sentiment weakens.
• Use call spreads instead of outright stock for bullish exposure in MAZE; upside is tied to a delayed catalyst, so defined-risk convexity is preferable to paying full delta into a long waiting period.
• If MAZE rallies back to pre-drawdown levels without new data, consider shorting into that strength for a 1-3 month trade, with a tight stop on any unexpectedly positive follow-up clinical readout.